All In Biotech

NDA 050625 · Novartis

Sandimmune

Cyclosporine · Oral · Calcineurin Inhibitor Immunosuppressant

Priority review

Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1990

Mar 2, 1990

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,166

250 Phase 3, 65 recruiting

FAERS reports

59,541

54,174 serious, 11,541 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RECOMMENDATIONS FOR USE, USE WITH CORTICOSTERIODS, RISKS WITH INAPPROPRIATE SWITCHING, and MONITORING CYCLOSPORINE BLOOD LEVELS Recommendations for Use Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Sandimmune. Patients receiving Sandimmune should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient. Use with Corticosteroids Sandimmune should be administered with adrenal corticosteroids but not with other immunosuppressive agents. Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Risks with Inappropriate Switching Between Neoral Capsules (MODIFIED) and Sandimmune...

What it is approved for

From the label in effect Jul 10, 2026.

INDICATIONS AND USAGE Sandimmune capsules and Sandimmune injection, in combination with adrenal corticosteroids, are indicated for the: Prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Treatment of chronic rejection in patients previously treated with other immunosuppressive agents. Because of the risk of anaphylaxis, Sandimmune injection should be reserved for patients who are unable to take the Sandimmune capsules.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 2, 1990 Original approval · Type 3 - New Dosage Form · priority review
3 products under this application
  • SANDIMMUNE · CYCLOSPORINE 100MG · CAPSULE, ORAL · Prescription · TE AB2
  • SANDIMMUNE · CYCLOSPORINE 50MG · CAPSULE, ORAL · Prescription · TE BX
  • SANDIMMUNE · CYCLOSPORINE 25MG · CAPSULE, ORAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Cyclosporine" as an intervention, any sponsor and status, largest first.

All 1,166 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective7,900
  • off label use7,898
  • product use in unapproved indication3,645
  • pyrexia2,998
  • diarrhoea2,325
  • condition aggravated2,180
  • nausea2,123
  • pneumonia2,085
  • cytomegalovirus infection2,033
  • hypertension1,802
  • sepsis1,776
  • fatigue1,767

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,059
20051,096
20061,185
20071,149
20081,939
20092,161
20101,898
20112,565
20121,719
2013758
2014878
2015861
20161,005
20171,285
20181,812
20192,498
20203,621
20213,670
20225,359
20235,487
20246,906
20256,085
20264,539

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sandimmune* (Cyclosporine)

2024 spending

$463K

Beneficiaries

108

549 claims

Per beneficiary

$4,288

$6.65 per unit

View as table
YearSpending
2020$1,176,436
2021$1,190,789
2022$1,147,267
2023$973,184
2024$463,102

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,071 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.